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Introduction {#sec005}
============

Caesarean section (CS) rates have been dramatically increasing over the past decades worldwide\[[@pone.0208725.ref001]\]. In the United States, more than 30% of pregnant women gave birth in the form of CS in 2006\[[@pone.0208725.ref002]\], while 46.2% of Chinese new-borns, the highest percentage in Asia, were delivered by CS in 2010\[[@pone.0208725.ref003]\]. Deep vein thrombosis (DVT), a blood clot in a deep vein of the leg or lower pelvis, is one of the most serious complications after CS. DVT causes lower limb dysfunction, thrombosis syndrome, and fatal pulmonary embolism (PE) in many serious cases, which is a leading cause of maternal morbidity and mortality. The incidence of DVT following CS is approximately 0.5%, and 0.5% to 2.0% of patients with DVT will suffer life-threatening PE\[[@pone.0208725.ref004],[@pone.0208725.ref005]\].

Given the serious consequences of DVT following CS, many mechanical preventive treatment strategies are often used in the postpartum period including early ambulation after surgery, graduated compression stockings, intermittent pneumatic compression, and others. Because of the lack of evidences, the benefits of pharmacologic thromboprophylaxis in preventing the occurrence of DVT in CS patients remain controversial. Guidelines from major societies, such as the Royal College of Obstetricians and Gynaecologists (RCOG), the American Congress of Obstetricians and Gynecologists (ACOG), and the American College of Chest Physicians (Chest), differ markedly in terms of criteria for identifying CS patients who should receive pharmacologic thromboprophylaxis\[[@pone.0208725.ref006],[@pone.0208725.ref007]\]; the guidelines are mainly based on expert opinions rather than evidence-based medicine from randomized or other clinical trials\[[@pone.0208725.ref008]\]. Therefore, it is important and necessary to evaluate the efficacy of pharmacologic thromboprophylaxis following CS. This systematic review based on available clinical trials to compare different thromboprophylaxis outcomes was performed.

Methods {#sec006}
=======

Inclusion and exclusion criteria {#sec007}
--------------------------------

Studies were included if they met both of the following criteria: 1) patients were treated with pharmacological thromboprophylaxis for preventing DVT following CS; and 2) articles were published in English.

Data sources and search strategy {#sec008}
--------------------------------

The search proceeded in PubMed, Embase and the Cochrane Library, including keyword and free word searches. The following search keywords were used: 'thrombophilia', 'thromboembolism', 'thromboprophylaxis', 'deep vein thrombosis', 'enoxaparin', 'heparin', 'caesarean section', 'Caesarean section', 'uterine-incision delivery', 'caesarean delivery', 'abdominal caesarean section'. In addition, this search was restricted to human trials with the final date of December 2017. The references of eligible articles were examined to filter further suitable articles. Endnote was used to remove duplicates and manage all references.

Study selection and data extraction {#sec009}
-----------------------------------

During the screening process, all articles were assessed by title and abstract based on the eligibility criteria. All potentially eligible studies were evaluated by reading full texts, and the studies that met the eligibility criteria were included in our systematic review. Two researchers independently extracted the following information from included studies: I) General characteristics of patients: age, weight and sample size. II) Intervention: type of thromboprophylaxis agent, dosage, duration, comparator including placebo, other agents, or no treatment. III) Outcomes: number of thrombosis-induced death/DVT/PE, major bleeding events and other adverse events. All processes were carried out separately by two researchers, and all disagreements were handled by discussion or consulting a third-party researcher.

Quality assessment {#sec010}
------------------

The methodological quality of RCTs was evaluated independently by two researchers using the Cochrane Collaboration's tool\[[@pone.0208725.ref009],[@pone.0208725.ref010]\]. For each of the seven domains, the study was ranked as high risk of bias, low risk of bias, or unclear risk of bias. The Newcastle-Ottawa Scale (NOS) was used to assess the bias risk of cohort studies with three factors including patient selection, comparability of groups, and outcome assessment. Studies were graded on an ordinal star scoring scale, with higher scores representing higher quality. The quality was ranked as high if it achieved 7 stars out of 9 points\[[@pone.0208725.ref011]\].

Statistical analysis {#sec011}
--------------------

Statistical analysis was conducted to estimate the Risk Ratios (RR) with 95% confidence intervals (CI) and to generate forest plots along with the heterogeneity assessment. The heterogeneity among studies was examined by the I-square (I^2^) statistic. If the I^2^ value was below 50%, a high degree of homogeneity was considered to exist among the studies. In this case, a fixed effects model was usedto replace a random effects model to estimate the RR\[[@pone.0208725.ref012]\].

Results {#sec012}
=======

Study selection {#sec013}
---------------

A total of 3118 articles were identified through the included databases. After removing 269 duplicates, 2849 articles were obtained by initial screening. A total of 2758 of 2849 articles in the initial screening were excluded by screening titles and abstracts. The remaining 91 articles were reviewed by reading the full text. As a result, 7 articles were enrolled in this systematic review ([Fig 1](#pone.0208725.g001){ref-type="fig"}).

![Flow chart of selection process.](pone.0208725.g001){#pone.0208725.g001}

Study characteristics {#sec014}
---------------------

Six RCTs\[[@pone.0208725.ref013]--[@pone.0208725.ref018]\] and one cohort study\[[@pone.0208725.ref019]\], published from 1998 to 2014, were included in this systematic review. Three studies were conducted in the United Kingdom\[[@pone.0208725.ref014],[@pone.0208725.ref016],[@pone.0208725.ref017]\], and the other four studies were from Australia\[[@pone.0208725.ref013]\], K.S.A.\[[@pone.0208725.ref015]\], Germany\[[@pone.0208725.ref018]\], and Italy\[[@pone.0208725.ref019]\]. This meta-analysis included a total of 1243 participants, with the sample size ranging from 17 to 529 cases. There were just two studies that distinguished patients with one or more risk factor of VTE following CS\[[@pone.0208725.ref014],[@pone.0208725.ref017]\], such as obesity, immobility, maternal age \> 35 years, parity \> 4, labour \> 12 h, gross varicose veins, current infection, pre-eclampsia, major current illness and CS performed as an emergency procedure.

Five studies\[[@pone.0208725.ref013],[@pone.0208725.ref015],[@pone.0208725.ref016],[@pone.0208725.ref018],[@pone.0208725.ref019]\] assessed the thromboprophylaxis efficacy of LMWH versus placebo, and two\[[@pone.0208725.ref017],[@pone.0208725.ref018]\] research studies evaluated the efficacy between LMWH and UFH. Additionally, differences in LMWH were compared by different product\[[@pone.0208725.ref014]\] and dose\[[@pone.0208725.ref017]\]. The duration of the interventions differed among the included 7 studies, ranging from 5 to 14 days ([Table 1](#pone.0208725.t001){ref-type="table"}).

10.1371/journal.pone.0208725.t001

###### General characteristics of the enrolled studies.

![](pone.0208725.t001){#pone.0208725.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                 Year   Country          Study design         Number   Intervention                                Age              Weight / BMI    Duration of prevention                                    
  -------------------------------------- ------ ---------------- -------------------- -------- ------------------------------------------- ---------------- --------------- ------------------------ ----------------- -------------- ---------
  Burrows RF\[[@pone.0208725.ref013]\]   2001   Australia        RCT                  76       dalteparin 2500 IU\                         Saline\          31.7±4.8        31.3±5.5                 81.7\[17.2\]      79.9\[14.0\]   5 days
                                                                                               (n = 39)                                    (n = 37)                                                                                   

  Ellison J\[[@pone.0208725.ref014]\]    2001   United Kingdom   RCT                  30\*     enoxaparin 4000 IU\                         NR               26(18--35)\     NR                       BMI\              NR             5 days
                                                                                               (n = 10)\                                                    27(16--42)\                              28.2(22--41)\                    
                                                                                               tinzaparin 50 IU/kg\                                         28(16--40)                               29.5(21--40.7)\                  
                                                                                               (n = 10)\                                                                                             27.8(23--39)                     
                                                                                               dalteparin 5000 IU\                                                                                                                    
                                                                                               (n = 10)                                                                                                                               

  Farjah A\[[@pone.0208725.ref015]\]     2012   K.S.A.           RCT                  300      tinzaparin 4500 IU\                         Placebo\         28.6 (18--35)   28.6 (18--35)            NR                NR             14 days
                                                                                               (n = 100)                                   (n = 200)                                                                                  

  Gates S\[[@pone.0208725.ref016]\]      2004   United Kingdom   RCT                  141      enoxaparin 40 mg\                           saline\          31.3±5.8        30.6±5.4                 ≥80 kg, 29%       ≥80 kg, 30%    14 days
                                                                                               (n = 70)                                    (n = 71)                                                                                   

  Gibson J L\[[@pone.0208725.ref017]\]   1998   United Kingdom   RCT                  17\*     enoxaparin 20 mg\                           UFH 7500IU ×2\   NR              NR                       NR                NR             NR
                                                                                               (n = 6)\                                    (n = 6)                                                                                    
                                                                                               enoxaparin 40 mg\                                                                                                                      
                                                                                               (n = 5)                                                                                                                                

  Gizzo S\[[@pone.0208725.ref019]\]      2014   Italy            Prospective Cohort   529      enoxaparin 4000 UI or dalteparin 5000 UI\   no treatment\    38.07±2.58      38.3±2.77                BMI\              BMI\           7 days
                                                                                               (n = 349)                                   (n = 180)                                                 27.14±2.16        27.48±1.93     

  Heilmann L\[[@pone.0208725.ref018]\]   2007   Germany          RCT                  150      dalteparin 5000 U\                          no treatment\    28±6\           28±3                     BMI\              BMI\           7 days
                                                                                               (n = 50)\                                   (n = 50)         29±5                                     23±4\             20±7           
                                                                                               UFH 5000 IU×2\                                                                                        23±2                             
                                                                                               (n = 50)                                                                                                                               
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: \*, in addition to CS, there was at least one additional risk factor for thrombosis

Quality assessment {#sec015}
------------------

In the six included RCTs, five studies in [Fig 2](#pone.0208725.g002){ref-type="fig"} were assessed to present an unclear risk of bias\[[@pone.0208725.ref013]--[@pone.0208725.ref017]\], while the sixth study was at high risk of bias\[[@pone.0208725.ref018]\]. In this high risk study, patients of the control group received no treatment, and failed blinding of participants and personnel was found. One cohort was determined as high quality: 8 stars\[[@pone.0208725.ref019]\].

![Risk of bias graph for 6 RCTs.](pone.0208725.g002){#pone.0208725.g002}

Efficacy evaluation {#sec016}
-------------------

Because of the different comparators, the included studies were assigned to three subgroups: LMWH versus negative control, LMWH versus UFH, and LMWH versus LMWH. In the first subgroup, analysis of all 5 studies\[[@pone.0208725.ref013],[@pone.0208725.ref015],[@pone.0208725.ref016],[@pone.0208725.ref018],[@pone.0208725.ref019]\] showed that LMWH and the negative control were associated with no obvious decrease in the risk of VTE, PE, or death related to VTE \[1.18, 95% *CI* = (0.28,4.91), *P* = 0.82\]. The observed *I*^*2*^ of 0% showed that there was no heterogeneity among these studies.

In the second subgroup, two studies\[[@pone.0208725.ref017],[@pone.0208725.ref018]\] including a total of 117 patients compared thromboprophylaxis of LMWH versus UFH. The outcomes of DVT and PE showed that the reduction of embolism was not significantly different \[0.33, 95% *CI* = (0.01,7.99), *P* = 0.50\] ([Table 2](#pone.0208725.t002){ref-type="table"}, [Fig 3](#pone.0208725.g003){ref-type="fig"}).

![Effect of all studies in reducing the incidence of embolism.\
(A) LMWH versus negative control; (B) LMWH versus UFH; (C) LMWH versus LMWH.](pone.0208725.g003){#pone.0208725.g003}

There were two studies\[[@pone.0208725.ref014],[@pone.0208725.ref017]\] involved in the last subgroup with only 41 patients, and the outcomes showed that no thrombosis occurred among all groups, such as those treated with enoxaparin, tinzaparin, and dalteparin.

10.1371/journal.pone.0208725.t002

###### Summary of the meta-analysis of thromboprophylaxis efficacy following CS.

![](pone.0208725.t002){#pone.0208725.t002g}

  Subgroup                       Included studies   N                  RR (95% CI)        *I*^*2*^ (%)   P (%)
  ------------------------------ ------------------ ------------------ ------------------ -------------- -------
  LMWH versus negative control   Overall            5                  1.18(0.28--4.91)   0              0.82
  RCTs                           4                  1.18(0.28--4.91)   0                  0.82           
  Cohort                         1                  NE                 NA                 NA             
  Unknown risk of VTE            5                  1.18(0.28--4.91)   0                  0.82           
  LMWH versus UFH                Overall            2                  0.33(0.01--7.99)   NA             0.50
  RCTs                           1                  0.33(0.01--7.99)   NA                 0.50           
  Unknown risk of VTE            1                  0.33(0.01--7.99)   NA                 0.50           
  High risk of VTE               1                  NE                 NA                 NA             
  LMWH versus LMWH               Overall            3                  NE                 NA             NA
  RCTs                           3                  NE                 NA                 NA             
  High risk of VTE               3                  NE                 NA                 NA             

Abbreviations: N, number of studies; RR, risk ratios; CI, confidence interval; P, P value for association; NE, not estimable; NA, not applicable.

Safety evaluation {#sec017}
-----------------

The reported adverse events in the 7 studies primarily included bleeding or haematomas, blood transfusions, allergic reactions, and serious wound complications such as wound infections requiring antibiotics, dehiscence, secondary sutures, and other treatment. All studies were assigned to the same subgroups based on a homologous comparator in efficacy evaluation.

In the first subgroup, the results of 4 studies\[[@pone.0208725.ref013],[@pone.0208725.ref016],[@pone.0208725.ref018],[@pone.0208725.ref019]\] showed that LMWH and the negative control were associated with an obvious increase in the risk of bleeding or haematomas \[8.47, 95% CI = (1.52, 47.11), *P* = 0.01\]. The highest relative risk increment of 11.89 times was observed in the study of Gizzo S\[[@pone.0208725.ref019]\], while the highest weight coefficient of 59.9% was found in Gate S\[[@pone.0208725.ref016]\]. The observed *I*^*2*^ of 0% showed that there was no heterogeneity among these studies in the risk of bleeding or haematomas. For other adverse events including blood transfusion, wound complications and allergic reactions, the incidences showed no significant differences. In the second subgroup of LMWH versus UFH, the risk of bleeding or haematomas was compared in two studies\[[@pone.0208725.ref017],[@pone.0208725.ref018]\] including a total of 117 patients: the result was not estimable, and the same conclusion was found regarding allergic reactions. For the last subgroup, the outcomes of occurrence rates of bleeding, haematomas or allergic reactions showed no significant differences among different products of LMWH ([Table 3](#pone.0208725.t003){ref-type="table"}, [Fig 4](#pone.0208725.g004){ref-type="fig"}).

![Safety of thromboprophylaxis following CS.\
A: LMWH versus negative control: (A1) Bleeding or hematomas; (A2) blood transfusion; (A3) wound complications; (A4) allergic reactions; B: LMWH versus UFH: (B1) Bleeding or hematomas; (B2) allergic reactions; C: LMWH versus LMWH: (C1) Bleeding or hematomas; (C2) allergic reactions.](pone.0208725.g004){#pone.0208725.g004}

10.1371/journal.pone.0208725.t003

###### Summary of the meta-analysis of thromboprophylaxis safety following CS.

![](pone.0208725.t003){#pone.0208725.t003g}

  subgroup                       Included studies   N                    Bleeding/ haematomas   N      Blood transfusion   N                  Wound complications   N      Allergic reactions                                                                           
  ------------------------------ ------------------ -------------------- ---------------------- ------ ------------------- ------------------ --------------------- ------ -------------------- ------------------- ------------------- ------ ------ ----- ----- ----- ----
  LMWH versus negative control   overall            4                    8.47 (1.52--47.11)     0      0.01                3                  2.48(0.04--146)       73     0.66                 3                   2.42(0.71--8. 24)   0      0.16   3     NE    NA    NA
  RCTs                           3                  6.17(0.76--49.96)    NA                     0.09   2                   0.32(0.01--7.54)   NA                    0.48   2                    1.94(0.50--7.44)    0                   0.34   3      NE    NA    NA    
  Cohort                         1                  11.89(0.70--200.7)   NA                     0.09   1                   17.07(1.03--282)   NA                    0.05   1                    4.65(0.25--85.97)   NA                  0.30   0      ---   ---   ---   
  Unknown risk of VTE            4                  8.47 (1.52--47.11)   0                      0.01   3                   2.48(0.04--146)    73                    0.66   3                    2.42(0.71--8. 24)   0                   0.16   3      NE    NA    NA    
  LMWH versus UFH                overall            2                    NE                     NA     NA                  0                  ---                   ---    ---                  0                   ---                 ---    ---    1     NE    NA    NA
  RCTs                           2                  NE                   NA                     NA     0                   ---                ---                   ---    0                    ---                 ---                 ---    1      NE    NA    NA    
  Unknown risk of VTE            1                  NE                   NA                     NA     0                   ---                ---                   ---    0                    ---                 ---                 ---    1      NE    NA    NA    
  high risk of VTE               1                  NE                   NA                     NA     0                   ---                ---                   ---    0                    ---                 ---                 ---    0      ---   ---   ---   
  LMWH versus LMWH               overall            3                    NE                     NA     NA                  0                  ---                   ---    ---                  0                   ---                 ---    ---    2     NE    NA    NA
  RCTs                           3                  NE                   NA                     NA     0                   ---                ---                   ---    0                    ---                 ---                 ---    2      NE    NA    NA    
                                 high risk of VTE   3                    NE                     NA     NA                  0                  ---                   ---    ---                  0                   ---                 ---    ---    2     NE    NA    NA

Abbreviations: N, number of studies; OR, odds ratio; CI, confidence interval; P, P value for association; NE, not estimable; NA, not applicable

Discussion {#sec018}
==========

Presently, the rate of CS, a significant risk factor for venous thromboembolism, has been steadily increasing over the past decades\[[@pone.0208725.ref001]\]. After CS, the incidences of PE and DVT are 0.06% and 0.04%, respectively, among the samples of the general population in Japan, which represent 22- and five-times higher risks than those after vaginal delivery\[[@pone.0208725.ref020],[@pone.0208725.ref021]\]. Based on the serious risk of thrombosis, post-caesarean thromboprophylaxis has been advocated even though the evidence is still limited. Mechanical thromboprophylaxis, such as elastic stockings (ES) or intermittent pneumatic compression (IPC), are recommended\[[@pone.0208725.ref008]\]. Due to a lack of evidence from appropriately sized randomized trials, pharmacological thromboprophylaxis such as heparin is controversial. Different guidelines include inconsistent recommendations regarding thromboprophylaxis for women undergoing CS. For instance, both the Royal College of Obstetricians and Gynaecologists (RCOG) \[[@pone.0208725.ref022]\] and the Society of Obstetric Medicine of Australia and New Zealand (SOMANZ)\[[@pone.0208725.ref023]\] recommend heparin thromboprophylaxis for all emergency CS, while the American College of Chest Physicians\[[@pone.0208725.ref024]\] suggests heparin only in the presence of another co-existing risk factor, such as excessive body mass index (BMI). Therefore, the absence of evidence leads to a wide variation among different guidelines on prophylactic strategies following CS.

In this systematic review, we evaluated the thromboprophylaxis efficacy following CS based on the latest clinical research. The efficacy results showed that there were no statistically significant differences in the risk of thrombus among LMWH versus negative control, LMWH versus UHF and LMWH versus LMWH, with all 7 related studies including RCTs and cohort. In the safety evaluation, LMWH was observed to increase the risk of bleeding or haematomas by 8.47 times compared with placebo, while other indicators such as blood transfusion, wound complications and allergic reactions showed no significant differences. In the other two subgroups, including LMWH versus UFH and LMWH versus LMWH, the incidences showed no significant differences.

There were several limitations in this systematic review. Most of the included RCTs, many of which included a small sample size such as 17 enrolled cases, were conducted in a single centre. In view of the low incidence of thrombotic events, larger samples are required for further validation. Moreover, the quality of the RCTs should be improved with regard to random sequence generation, allocation concealment, and blinding of participants and personnel.

Conclusions {#sec019}
===========

Taken together, our studies indicate that there is insufficient evidence on which to base recommendations for pharmacologic thromboprophylaxis following CS. Large-scale, high-quality trials are warranted to evaluate the effectiveness of intervention.
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